Policy positions

This policy position describes the Convention of Biological Diversity and Nagoya Protocol, as well as the need to ensure free and rapid access to pathogens, sequences, and related information to protect public health and promote pandemic preparedness. 

Antimicrobial resistance is one of the World Health Organization’s top ten threats to global health; in this policy position, we outline how GSK is getting ahead of the challenge and potential policy solutions.

This paper describes GSK's approach to conducting clinical trials. It sets out the philosophy underpinning our approach and addresses issues including where we conduct our studies, the standard of care we apply and access to medicines post-trial.

This policy position details GSK's uses of cloning, gene modification, and stem cell technologies for drug discovery and development to advance medical research. 

This paper summarises our position on “conflict minerals”, including any use of them in our products; our commitment to reduce and ultimately replace any use of “conflict minerals” in our products that benefits armed groups in the “Covered Countries”; and the processes we have in place to meet this commitment.

In this policy position, we focus on commitments to data transparency for GSK sponsored studies.

This paper sets out our approach to working with patient organisations; why we engage with them; and the standards we apply to ensure our interactions are appropriate, ethical and transparent. 

In this policy position, we provide our perspective on managing sustainability across our value chain – including limiting our carbon footprint; water stewardship; managing waste; and sustainable, deforestation-free sourcing.

In this policy position, we detail our commitment to minimising the risk of harm to our patients from falsified GSK products and to ensuring the quality of genuine GSK products through strict compliance with internal standards and with regulations. 

This paper focuses on GSK’s use of chemicals during clinical development, in our manufacturing operations and in our marketed products.

In this policy position, we set out our commitments to promote and uphold human rights through our engagements with patients, our employees, our suppliers, the communities in which we live and operate and our environment. 

In this paper we set out the core principles underpinning our position on IP and the approach we take on patents and licensing. 

As a science-led healthcare company, we believe our medicines should be used consistently with our purpose, which is to unite science, talent and technology to get ahead of disease together. 

Currently, we are not aware of any GSK products being included in any lethal injection protocol; however, in keeping with our purpose, we would be opposed to such a use.

This paper sets out what we believe to be an effective and responsible approach to assess and manage potential risks associated with the use of genetically modified materials.

In this policy position, we outline how we are addressing potential risks of pharmaceuticals which may enter the environment.

This position sets out GSK’s commitment to high safety, quality, and ethical standards through application of consistent pharmacovigilance principles.

In all of our political engagements, we are committed to ensuring that we adhere to the highest ethical standards and legislative requirements. This paper sets out our approach to political advocacy or “lobbying” activities.

This policy position sets our approach and views on increasing access to our medicines and vaccines through responsible pricing that is accessible for patients and sustainable for our business; strategic access programmes; and partnerships.

This paper sets out GSK’s view on the role of AI in biopharma, our commitments to develop and use AI responsibly, and actions policymakers can take to support safe and effective AI adoption.

This policy position sets out current and future approaches to animal use and our commitments and responsibilities to ensuring high standards of care, welfare and treatment for animals involved in research and development and quality control.

This is GSK’s tax strategy for 2024.

This paper sets out our approach to investing in and supporting LLMICs with technology transfer and capacity building, including through skills development and health systems strengthening.

There will be occasions when it may be appropriate for patients to have access to our unlicensed medicines outside of a clinical trial. This paper sets out our approach to the treatment use of our unlicensed pharmaceutical products and vaccines (referred to as investigational medicines) and the criteria we use to assess requests from healthcare professionals. 

This position statement summarises our approach to working with Third Parties. It sets out the minimum standards we expect of them, as well as other areas of importance to us.